Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma

Jeddo,Salim F.A.; Wei,Xianfu; Li,Ka; Li,Xin; Yang,Qiang; Dongol,Samina; Li,Jianmin

doi:10.3892/or.2020.7686

Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma

Authors:
- Salim F.A. Jeddo
- Xianfu Wei
- Ka Li
- Xin Li
- Qiang Yang
- Samina Dongol
- Jianmin Li
View Affiliations

Affiliations: Department of Orthopedics, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: July 13, 2020 https://doi.org/10.3892/or.2020.7686
Pages: 1037-1048
Copyright: © Jeddo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common primary malignancy of bones and frequently affects young children and adolescents. There are several challenges associated with treating osteosarcoma owing to the aggressiveness of the disease, as well as the risk of chemoresistance. Numerous studies are being performed with the aim of identifying improved prognostic and therapeutic markers for this malignancy. Maternal embryonic leucine zipper kinase (MELK) is an oncogene that has been studied in several types of cancer in recent years. In the present study, the expression of MELK in osteosarcoma and normal tissue samples was examined, and the effects of MELK expression on osteosarcoma cellular proliferation, metastasis, the cell cycle and apoptosis were demonstrated using CCK‑8, wound healing, migration and invasion and apoptosis assays. The role of MELK in cancer progression in osteosarcoma was determined, revealing the association between MELK expression and prognosis of osteosarcoma. It was demonstrated that knockdown of MELK resulted in reduced proliferation, migration and invasion in vitro along with potentiation of apoptosis and cell cycle arrest. Furthermore, the effect of the targeted MELK inhibitor, OTSSP167, on tumor progression of osteosarcoma in vitro and in vivo was assessed. Mechanistically, it was demonstrated that MELK promoted osteosarcoma proliferation and metastasis by regulating PCNA and MMP9 expression via the PI3K/Akt/mTOR signaling pathway. Thus, the present study revealed the oncogenic role played by MELK, and established MELK as a valuable prognostic and therapeutic marker in osteosarcoma.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, et al: Bone cancer. J Natl Compr Canc Netw. 11:688–723. 2013. View Article : Google Scholar : PubMed/NCBI
3	Lindsey BA, Markel JE and Kleinerman ES: Osteosarcoma overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
4	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Pediatric and adolescent osteosarcoma (US). Springer. 152:3–13. 2009. View Article : Google Scholar
6	Bacci G, Longhi A, Bertoni F, Briccoli A, Versari M, Pignotti E and Picci P: Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy. The Rizzoli experience in 52 patients. Acta Orthopaed. 77:938–943. 2006. View Article : Google Scholar
7	Heyer BS, Warsowe J, Solter D, Knowles BB and Ackerman SL: New member of the SNF1/AMPK kinase family, Melk, is expressed in the mouse egg and preimplantation embryo. Mol Reprod Dev. 47:148–156. 1997. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y, Zhou X, Li Y, Xu Y, Lu K, Li P and Wang X: Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. Oncogene. 37:5520–5533. 2018. View Article : Google Scholar : PubMed/NCBI
9	Jiang P and Zhang D: Maternal embryonic leucine zipper kinase (MELK): A novel regulator in cell cycle control, embryonic development, and cancer. Int J Mol Sci. 14:21551–21560. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ganguly R, Hong CS, Smith LG, Kornblum HI and Nakano I: Maternal embryonic leucine zipper kinase: Key kinase for stem cell phenotype in glioma and other cancers. Mol Cancer Ther. 13:1393–1398. 2014. View Article : Google Scholar : PubMed/NCBI
11	Janostiak R, Rauniyar N, Lam TT, Ou J, Zhu LJ, Green MR and Wajapeyee N: MELK promotes melanoma growth by stimulating the NF-κB pathway. Cell Rep. 21:2829–2841. 2017. View Article : Google Scholar : PubMed/NCBI
12	Li G, Yang M, Zuo L and Wang MX: MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells. Oncol Lett. 15:9934–9940. 2018.PubMed/NCBI
13	Kohler RS, Kettelhack H, Knipprath-Mészaros AM, Fedier A, Schoetzau A, Jacob F and Heinzelmann-Schwarz V: MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. Gynecol Oncol. 145:159–166. 2017. View Article : Google Scholar : PubMed/NCBI
14	Li S, Li Z, Guo T, Xing XF, Cheng X, Du H, Wen XZ and Ji JF: Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer. Oncotarget. 7:6266–6280. 2016. View Article : Google Scholar : PubMed/NCBI
15	Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H, et al: Maternal embryonic leucine Zipper Kinase/Murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res. 65:9751–9761. 2005. View Article : Google Scholar : PubMed/NCBI
16	Wu S, Chen X, Hu C, Wang J, Shen Y and Zhong Z: Up-regulated maternal embryonic leucine zipper kinase predicts poor prognosis of hepatocellular carcinoma patients in a Chinese Han population. Med Sci Monit. 23:5705–5713. 2017. View Article : Google Scholar : PubMed/NCBI
17	Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, Mourtada-Maarabouni M and Williams GT: Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res. 11:R602009. View Article : Google Scholar : PubMed/NCBI
18	Chung S and Nakamura Y: MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells. Cell Cycle. 12:1655–1656. 2013. View Article : Google Scholar : PubMed/NCBI
19	Chung S, Suzuki H, Miyamoto T, Takamatsu N, Tatsuguchi A, Ueda K, Kijima K, Nakamura Y and Matsuo Y: Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 3:1629–1640. 2012. View Article : Google Scholar : PubMed/NCBI
20	Liu D, Zhang XX, Li MC, Cao CH, Wan DY, Xi BX, Tan JH, Wang J, Yang ZY, Feng XX, et al: C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 9:17392018. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Chen G and Deng X: Cell synchronization by double thymidine block. Bio Protoc. 8:e29942018. View Article : Google Scholar : PubMed/NCBI
23	Ganguly R, Mohyeldin A, Thiel J, Kornblum HI, Beullens M and Nakano I: MELK-a conserved kinase: Functions, signaling, cancer, and controversy. Clin Transl Med. 4:112015. View Article : Google Scholar : PubMed/NCBI
24	Lin ML, Park JH, Nishidate T, Nakamura Y and Katagiri T: Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res. 9:R172007. View Article : Google Scholar : PubMed/NCBI
25	Strzalka W and Ziemienowicz A: Proliferating cell nuclear antigen (PCNA): A key factor in DNA replication and cell cycle regulation. Ann Bot. 107:1127–1140. 2011. View Article : Google Scholar : PubMed/NCBI
26	Müller R, Misund K, Holien T, Bachke S, Gilljam KM, Våtsveen TK, Rø TB, Bellacchio E, Sundan A and Otterlei M: Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 8:e704302013. View Article : Google Scholar : PubMed/NCBI
27	Wang X, Wang D, Yuan N, Liu F, Wang F, Wang B and Zhou D: The prognostic value of PCNA expression in patients with osteosarcoma: A meta-analysis of 16 studies. Medicine (Baltimore). 96:e82542017. View Article : Google Scholar : PubMed/NCBI
28	Jabłońska-Trypuć A, Matejczyk M and Rosochacki S: Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 31 (Suppl 1):S177–S183. 2016. View Article : Google Scholar
29	Viros D, Camacho M, Zarraonandia I, García J, Quer M, Vila L and León X: Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy. Oral Oncol. 49:322–325. 2013. View Article : Google Scholar : PubMed/NCBI
30	Vilen ST, Salo T, Sorsa T and Nyberg P: Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. ScientificWorldJournal. 2013:9205952013. View Article : Google Scholar : PubMed/NCBI
31	Zhou J, Liu T and Wang W: Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: A meta-analysis of 16 studies. Medicine (Baltimore). 97:e130512018. View Article : Google Scholar : PubMed/NCBI
32	Zhou HY, Yao XM, Chen XD, Tang JM, Qiao ZG and Wu XY: Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 23:10283–10289. 2019.PubMed/NCBI
33	Ou JM, Qiu MK, Dai YX, Dong Q, Shen J, Dong P and Fei ZW: Combined Blockade and Akt/mTOR pathway inhibits growth of human hemangioma via downregulation of proliferating cell nuclear antigen. Int J Immunopathol Pharmacol. 25:945–953. 2012. View Article : Google Scholar : PubMed/NCBI
34	Olaisen C, Muller R, Nedal A and Otterlei M: PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling. Cell Signal. 27:1478–1487. 2015. View Article : Google Scholar : PubMed/NCBI
35	Dobbin ZC and Landen CN: The importance of the PI3K/AKT/mTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
36	Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI and Boyd J: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 11:2875–2878. 2005. View Article : Google Scholar : PubMed/NCBI
37	Matsuoka T and Yashiro M: The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel). 6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
38	Ji W, Arnst C, Tipton AR, Bekier ME II, Taylor WR, Yen TJ and Liu ST: OTSSP167 abrogates mitotic checkpoint through inhibiting multiple mitotic kinases. PLoS One. 11:e01535182016. View Article : Google Scholar : PubMed/NCBI
39	Lee JJ, Loh K and Yap YS: PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 12:342–354. 2015.PubMed/NCBI